Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for proliferation of antigen-specific T cells

A specific and antigenic technology, applied in the field of immunology and cancer therapy, can solve the problems of unpredictable in vivo efficacy and poor effect

Active Publication Date: 2015-07-15
IMMUNICUM
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is now understood that these criteria alone do not predict in vivo potency
Gattinoni et al., J. Clin. Invest. 115:1616-1626 (2005) found that CD8 acquired full effector properties and showed enhanced anti-tumor reactivity in vitro + T cells, less effective at triggering tumor regression and cure in vivo
[0008] Methods according to prior art require one or more restimulations to achieve clinically relevant levels of tumor-specific cytotoxic T cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for proliferation of antigen-specific T cells
  • Method for proliferation of antigen-specific T cells
  • Method for proliferation of antigen-specific T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Materials and methods : In tissue culture flasks, gamma-irradiated PBMCs from healthy blood donors were compared with those from allogeneic donors (relative to healthy donors) at a ratio of 1:1 in serum-free X-VIVO 15 medium. Unirradiated PBMC were co-cultured for 5-7 days to generate allo-sensitized allogeneic lymphocytes (ASAL) in a standard one-way mixed lymphocyte reaction (MLR). For proliferation of immature DCs, peripheral blood mononuclear cells (PBMCs) obtained from healthy blood donors were isolated on a density gradient (Lymphoprep, Nycomed, Oslo, Norway). Separated PBMCs were resuspended on AIM-V (Invitrogen, Paisley, UK) medium, and 2.5 × 10 6 Cells were plated per well in a 24-well plastic culture plate and allowed to adhere for 2 hours. Non-adherent cells were removed, and the remaining adherent monocytes were incubated in AIM-V medium supplemented with recombinant human GM-CSF and IL-4 (R&D Systems, Abingdon, UK; both 1,000 U / mL). Cultured in medium f...

Embodiment 2

[0092] Materials and methods : ASAL was produced during conventional MLR for 7 days using irradiated allogeneic PBMCs as stimuli (see Example 1). After harvesting and irradiation, ASAL ("MLR") or depleted CD4 + , CD8 + or CD56 + Mixed ASAL populations of (NK / NKT) were co-cultured with mature allogeneic monocyte-derived DCs (autologous to the PBMCs used to elicit ASAL). Co-culture supernatants were collected after 24 hours and subsequently assayed for IL-2, IL-2 and IFN-γ production.

[0093] result : The production of IL-2 was found to be strictly CD4-dependent ( Figure 6 A), while IL-12 produces ( Figure 6 B) shows complete absence of ASAL-dependence and IFN-γ production ( Figure 6 C) Shows partial dependence on co-cultured and allogeneic challenged CD4 in the ASAL population + , CD8 + and CD56 + (NK / NKT).

Embodiment 3

[0095] Materials and methods : Generation of immature DCs by plastic-adhered monocytes. After adding 1000U / mL of IL-4 and GM-CFS Monocytes were cultured in DC for 7 days. During the last 2 days of incubation, DCs were induced to mature by adding 50 ng / mL TNF-α, 25 ng / mL IL-1β, 50 ng / mL IFN-γ, 3000 U / mL IFN-α and 20 μg / mL poly I:C.

[0096] ASAL was produced in a one-way mixed lymphocyte reaction by co-culturing gamma-irradiated PBMCs with non-irradiated autologous PBMCs relative to DC donors at a 1:1 ratio in X-VIVO 15 for 7 days.

[0097] From adding 50ng / mL IL-15 (final concentration is 0.5×10 6 Lymphocytes / mL) CD8 was isolated by positive selection from autologous PBMC cultured in X-VIVO15 for 7 days + T lymphocytes. Centrifuge PBMCs and resuspend in PBS-0.5% BSA-2M EDTA to a final concentration of 1 x 10 7 / 80 μL. Combine PBMCs with CD8 + Microbeads (Miltenyi Biotec) were incubated at 4°C for 15 minutes, washed, resuspended and placed on an LS MACS column. Unlab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a tumor. The invention is also directed to the composition obtained by the method and uses thereof.

Description

technical field [0001] The present invention relates to the fields of immunology and cancer therapy, and more specifically relates to a method for activating antigen-specific T cells and T cells prepared by the method. Background technique [0002] T cells recognize tumor or infected cells and prevent disease by killing these target cells. However, the interaction of tumors or pathogens with the immune system is complex, as evidenced by the development of cancer or chronic infectious diseases in the presence of specific T cells, thus pathogens or tumors can apparently evade T cell surveillance. [0003] The ability of T cells to detect virtually any pathogenic invader results from their very diverse receptor repertoire, which allows the T cell pool to recognize a large number of peptides presented by major histocompatibility complex (MHC) molecules. Furthermore, signaling through the T cell receptor (TCR) (signal 1) is not sufficient to generate sufficient T cell activation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/0783A61P35/00A61K39/00
CPCA61K39/0011A61K2039/5158A61K2039/57A61P35/00A61P37/04A61P43/00A61K39/4621C12N5/0645A61K39/4611A61K39/464406C12N5/0639A61K2239/26A61K39/46434C12N5/0636A61K39/001106A61K39/00115A61K39/001191A61K39/001194A61K39/001151
Inventor 亚历克斯·卡尔松-帕拉安娜-卡林·瓦尔格伦本特·安德松
Owner IMMUNICUM